Back to Search Start Over

Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity.

Authors :
Bota-Rabassedas N
Banerjee P
Niu Y
Cao W
Luo J
Xi Y
Tan X
Sheng K
Ahn YH
Lee S
Parra ER
Rodriguez-Canales J
Albritton J
Weiger M
Liu X
Guo HF
Yu J
Rodriguez BL
Firestone JJA
Mino B
Creighton CJ
Solis LM
Villalobos P
Raso MG
Sazer DW
Gibbons DL
Russell WK
Longmore GD
Wistuba II
Wang J
Chapman HA
Miller JS
Zong C
Kurie JM
Source :
Cell reports [Cell Rep] 2021 Apr 20; Vol. 35 (3), pp. 109009.
Publication Year :
2021

Abstract

Cancer cells function as primary architects of the tumor microenvironment. However, the molecular features of cancer cells that govern stromal cell phenotypes remain unclear. Here, we show that cancer-associated fibroblast (CAF) heterogeneity is driven by lung adenocarcinoma (LUAD) cells at either end of the epithelial-to-mesenchymal transition (EMT) spectrum. LUAD cells that have high expression of the EMT-activating transcription factor ZEB1 reprogram CAFs through a ZEB1-dependent secretory program and direct CAFs to the tips of invasive projections through a ZEB1-driven CAF repulsion process. The EMT, in turn, sensitizes LUAD cells to pro-metastatic signals from CAFs. Thus, CAFs respond to contextual cues from LUAD cells to promote metastasis.<br />Competing Interests: Declaration of interests D.L.G. serves on scientific advisory committees for AstraZeneca, GlaxoSmithKline, Sanofi, and Janssen; provides consultation to Ribon Therapeutics; and receives research support from Janssen, Takeda, and AstraZeneca. I.I.W. serves on advisory boards for Genentech/Roche, Bristol-Myers Squibb, Medscape, Astra Zeneca/Medimmune, HTG Molecular, Merck, GlaxoSmithKline, and MSD and receives research support from Genentech, Oncoplex, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, 4D, Novartis, and Perkin-Elmer (Akoya). G.D.L. has received financial support from Pfizer-CTI. J.M.K. has received consulting fees from Halozyme. P.B. has received consulting fees from ExpertConnect.<br /> (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
2211-1247
Volume :
35
Issue :
3
Database :
MEDLINE
Journal :
Cell reports
Publication Type :
Academic Journal
Accession number :
33882319
Full Text :
https://doi.org/10.1016/j.celrep.2021.109009